Hemodialysis is the main method of clinical renal replacement therapy, and its effectiveness and safety have been widely confirmed. High-flux hemodialysis, as a constantly updating new mode in the field of blood purif...Hemodialysis is the main method of clinical renal replacement therapy, and its effectiveness and safety have been widely confirmed. High-flux hemodialysis, as a constantly updating new mode in the field of blood purification, has effectively improved the efficiency of hemodialysis and reduced the incidence of hemodialysis complications. High-flux hemodialysis has been widely used in clinical practice, and mainly plays its role through adsorption, convection and dispersion. High-flux hemodialysis has some advantages not possessed by conventional hemodialysis, including protecting injured renal function, reducing the incidence of cardiovascular complications in hemodialysis patients, improving the patients' nutritional status, reducing the occurrence of renal osteopathy and delaying the occurrence time of dialysis-associated amyloidosis. However, high-flux hemodialysis also has some limitations, such as the elimination of drugs and nutrients, and the backfiltration caused by increased pressure on the dialysis membrane and dialysate side. In this review, the related progress of high-flux hemodialysis in clinical application, mechanism, complications and treatment are discussed in order to provide a reference for its more rational clinical use.展开更多
目的分析心脏移植受者术后发生高钾血症的预后、危险因素及其预测指标。方法回顾性分析158例受者的临床资料,根据受者术后随访1年内的血钾水平分为正常血钾组(83例)、高钾血症组(43例)及重度高钾血症组(32例)。总结心脏移植术后高钾血...目的分析心脏移植受者术后发生高钾血症的预后、危险因素及其预测指标。方法回顾性分析158例受者的临床资料,根据受者术后随访1年内的血钾水平分为正常血钾组(83例)、高钾血症组(43例)及重度高钾血症组(32例)。总结心脏移植术后高钾血症的发生情况及预后,分析心脏移植术后高钾血症的危险因素及预测指标。结果心脏移植术后1年高钾血症发生率为47.5%(75/158),重度高钾血症发生率20.3%(32/158)。重度高钾血症组的病死率为16%(5/32),高于正常血钾组的8%(7/83)和高钾血症组的7%(3/43)。术前半年血清肌酐(Scr)平均值、术前末次总胆红素、术后血液透析时间、术后1 d Scr及术后1 d脑钠肽前体是心脏移植术后发生高钾血症的独立危险因素(均为P<0.05)。术前半年Scr平均值、术后血液透析时间和术后1 d Scr、术后7 d Scr可预测术后重度高钾血症。结论心脏移植术后重度高钾血症的结局欠佳,心脏移植术后发生高钾血症的独立危险因素包括术前半年Scr平均值、术前末次总胆红素、术后血液透析时间、术后1 d Scr及术后1 d脑钠肽前体,围手术期Scr及术后血液透析时间可预测心脏移植术后1年内重度高钾血症。展开更多
目的探讨罗沙司他对尿毒症维持性血液透析肾性贫血患者的疗效影响及其作用机制。方法选择2018年5月至2021年1月南京市中心医院收治的100例尿毒症维持性血液透析肾性贫血患者为研究对象,依照治疗方法不同分为对照组(60例)和研究组(40例)...目的探讨罗沙司他对尿毒症维持性血液透析肾性贫血患者的疗效影响及其作用机制。方法选择2018年5月至2021年1月南京市中心医院收治的100例尿毒症维持性血液透析肾性贫血患者为研究对象,依照治疗方法不同分为对照组(60例)和研究组(40例)。对照组接受重组人促红+素注射液治疗,研究组接受罗沙司他治疗,两组均治疗12周。对比两组临床疗效,对比两组治疗前后低密度脂蛋白(low density lipoprotein,LDL)、甘油三酯(triacylglycerol,TG)、血清C反应蛋白(C-reactive protein,CRP)、转铁蛋白饱和度、铁蛋白、铁调素水平,对比两组药物安全性。结果研究组总有效率(90.00%)高于对照组(77.33%),差异有显著性(P<0.05);治疗前,两组LDL、TG水平比较,差异无显著性(P>0.05);治疗12周后,两组LDL、TG水平均降低(P<0.05),且研究组更低(P<0.05);治疗前,两组血清CRP水平比较,差异无显著性(P>0.05);治疗12周后,两组血清CRP水平均降低(P<0.05)且研究组更低,差异有显著性(P<0.05);治疗前,两组血清转铁蛋白饱和度、铁蛋白、铁调素水平比较,差异无显著性(P>0.05);治疗12周后,两组血清转铁蛋白饱和度水平均升高,且研究组更高,差异有显著性(P<0.05);治疗12周后,两组血清铁蛋白、铁调素水平均降低且研究组更低,差异有显著性(P<0.05);两组治疗12周内不良反应发生率比较,差异无显著性(P>0.05)。结论罗沙司他治疗尿毒症维持性血液透析肾性贫血患者疗效显著,可改善患者血脂代谢水平,减轻机体炎症反应,安全可靠,且其作用机制与调节铁代谢密切相关。展开更多
文摘Hemodialysis is the main method of clinical renal replacement therapy, and its effectiveness and safety have been widely confirmed. High-flux hemodialysis, as a constantly updating new mode in the field of blood purification, has effectively improved the efficiency of hemodialysis and reduced the incidence of hemodialysis complications. High-flux hemodialysis has been widely used in clinical practice, and mainly plays its role through adsorption, convection and dispersion. High-flux hemodialysis has some advantages not possessed by conventional hemodialysis, including protecting injured renal function, reducing the incidence of cardiovascular complications in hemodialysis patients, improving the patients' nutritional status, reducing the occurrence of renal osteopathy and delaying the occurrence time of dialysis-associated amyloidosis. However, high-flux hemodialysis also has some limitations, such as the elimination of drugs and nutrients, and the backfiltration caused by increased pressure on the dialysis membrane and dialysate side. In this review, the related progress of high-flux hemodialysis in clinical application, mechanism, complications and treatment are discussed in order to provide a reference for its more rational clinical use.
文摘目的分析心脏移植受者术后发生高钾血症的预后、危险因素及其预测指标。方法回顾性分析158例受者的临床资料,根据受者术后随访1年内的血钾水平分为正常血钾组(83例)、高钾血症组(43例)及重度高钾血症组(32例)。总结心脏移植术后高钾血症的发生情况及预后,分析心脏移植术后高钾血症的危险因素及预测指标。结果心脏移植术后1年高钾血症发生率为47.5%(75/158),重度高钾血症发生率20.3%(32/158)。重度高钾血症组的病死率为16%(5/32),高于正常血钾组的8%(7/83)和高钾血症组的7%(3/43)。术前半年血清肌酐(Scr)平均值、术前末次总胆红素、术后血液透析时间、术后1 d Scr及术后1 d脑钠肽前体是心脏移植术后发生高钾血症的独立危险因素(均为P<0.05)。术前半年Scr平均值、术后血液透析时间和术后1 d Scr、术后7 d Scr可预测术后重度高钾血症。结论心脏移植术后重度高钾血症的结局欠佳,心脏移植术后发生高钾血症的独立危险因素包括术前半年Scr平均值、术前末次总胆红素、术后血液透析时间、术后1 d Scr及术后1 d脑钠肽前体,围手术期Scr及术后血液透析时间可预测心脏移植术后1年内重度高钾血症。
文摘目的探讨罗沙司他对尿毒症维持性血液透析肾性贫血患者的疗效影响及其作用机制。方法选择2018年5月至2021年1月南京市中心医院收治的100例尿毒症维持性血液透析肾性贫血患者为研究对象,依照治疗方法不同分为对照组(60例)和研究组(40例)。对照组接受重组人促红+素注射液治疗,研究组接受罗沙司他治疗,两组均治疗12周。对比两组临床疗效,对比两组治疗前后低密度脂蛋白(low density lipoprotein,LDL)、甘油三酯(triacylglycerol,TG)、血清C反应蛋白(C-reactive protein,CRP)、转铁蛋白饱和度、铁蛋白、铁调素水平,对比两组药物安全性。结果研究组总有效率(90.00%)高于对照组(77.33%),差异有显著性(P<0.05);治疗前,两组LDL、TG水平比较,差异无显著性(P>0.05);治疗12周后,两组LDL、TG水平均降低(P<0.05),且研究组更低(P<0.05);治疗前,两组血清CRP水平比较,差异无显著性(P>0.05);治疗12周后,两组血清CRP水平均降低(P<0.05)且研究组更低,差异有显著性(P<0.05);治疗前,两组血清转铁蛋白饱和度、铁蛋白、铁调素水平比较,差异无显著性(P>0.05);治疗12周后,两组血清转铁蛋白饱和度水平均升高,且研究组更高,差异有显著性(P<0.05);治疗12周后,两组血清铁蛋白、铁调素水平均降低且研究组更低,差异有显著性(P<0.05);两组治疗12周内不良反应发生率比较,差异无显著性(P>0.05)。结论罗沙司他治疗尿毒症维持性血液透析肾性贫血患者疗效显著,可改善患者血脂代谢水平,减轻机体炎症反应,安全可靠,且其作用机制与调节铁代谢密切相关。